Literature DB >> 7521831

Race and hypertension. What is clinically relevant?

D R Rutledge1.   

Abstract

Hypertension, once considered rare in Africa, occurs frequently in most Black populations outside of the continent as well as within more urban areas of Africa. The frequency of hypertension in Black citizens of the US is among the highest in the world. Pathophysiological mechanisms suggest the frequency of salt-sensitive blood pressure is more common in Black patients. More Black than White patients initially present with volume expansion. However, in Black patients there appears to be no significant relationship between plasma renin activity, plasma volume and blood pressure. The syndrome of insulin resistance has also been reported in African Americans. Future studies should address this issue, both because it relates to identifying individuals at risk for development of high blood pressure and because it has implications for initial selection of antihypertensive therapy. Hypertensive kidney disease is prevalent in Black people. Lowering the blood pressure with diuretic-based therapies has not been shown to delay or prevent the loss of kidney function in patients with this condition, suggesting that this treatment approach may not be optimal. Lifestyle modifications remain the initial therapeutic regimen. Because diuretics and beta-blockers have been shown to reduce cardiovascular morbidity and mortality in controlled clinical trials, they are preferred therapies. The Hypertension Detection and Follow-up Program showed significant reductions in morbidity and mortality in Black patients using primarily diuretic-based therapies. However, controversy persists regarding use of diuretics since some investigators believe that greater reductions in overall cardiovascular risk may be achieved in Black patients using other agents. These agents may eventually be able to exert a beneficial cardiovascular effect in addition to and independent of their blood pressure-lowering effect. Long term data documenting reduced morbidity and mortality rates with other agents are needed for all populations, particularly in Black hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521831     DOI: 10.2165/00003495-199447060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  135 in total

1.  Serum-insulin in essential hypertension and in peripheral vascular disease.

Authors:  T A Welborn; A Breckenridge; A H Rubinstein; C T Dollery; T R Fraser
Journal:  Lancet       Date:  1966-06-18       Impact factor: 79.321

2.  Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; W P Castelli; J R Margolis
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

3.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

4.  Hypotensive and sedative effects of insulin in autonomic failure.

Authors:  C J Mathias; D F da Costa; P Fosbraey; N J Christensen; R Bannister
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

Review 5.  Management of hypertension: considerations involving cardiovascular risk reduction.

Authors:  N K Hollenberg
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  Definitions and characteristics of sodium sensitivity and blood pressure resistance.

Authors:  M H Weinberger; J Z Miller; F C Luft; C E Grim; N S Fineberg
Journal:  Hypertension       Date:  1986-06       Impact factor: 10.190

7.  The arthritic patient with hypertension: selection of an NSAID.

Authors:  J D Spence
Journal:  Scand J Rheumatol Suppl       Date:  1986

Review 8.  Role of insulin resistance in human disease (syndrome X): an expanded definition.

Authors:  G M Reaven
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

9.  Race and ethnicity as biological constructs.

Authors:  F L Jackson
Journal:  Ethn Dis       Date:  1992       Impact factor: 1.847

10.  Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study.

Authors:  J H Fuller; M J Shipley; G Rose; R J Jarrett; H Keen
Journal:  Lancet       Date:  1980-06-28       Impact factor: 79.321

View more
  2 in total

1.  AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns.

Authors:  Marilyn N Martinez; Iain McGilveray
Journal:  AAPS PharmSci       Date:  2003-10-23

2.  MOG antibody-associated disease presenting with tumefactive lesions and closed-ring enhancement.

Authors:  Yin-Xi Zhang; Yang Zheng; Meng-Ting Cai; Qiang Du; Mei-Ping Ding
Journal:  Acta Neurol Belg       Date:  2021-05-25       Impact factor: 2.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.